Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: bentamapimod, tanzisertib, cc-401 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 204 | 0.76 |
| pathways Reactome | 5 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 7127
Sealed predictions
- MAPK9 in dopamine neurons, braak+0.47 (p 0.204) → -0.19 (p 0.630)receipt 7134
Swarm cases
receipt 7134: MAPK9 in dopamine neurons, braak
- power
- full sample +0.29 (p 0.239, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.246, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.258, n 18). could be the mix.
- skeptic
- leave-one-out range +0.20 to +0.41, sign flips 0; without severely affected donors +0.29 (p 0.239, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAPK9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts